Class information for:
Level 1: NEBIVOLOL//VASODILATING BETA BLOCKERS//NEBIVOLOL HYDROCHLORIDE

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
19038 458 34.2 74%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
895 10656 CARVEDILOL//NEBIVOLOL//BETA BLOCKERS

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 NEBIVOLOL Author keyword 186 59% 46% 210
2 VASODILATING BETA BLOCKERS Author keyword 13 80% 2% 8
3 NEBIVOLOL HYDROCHLORIDE Author keyword 10 73% 2% 8
4 THIRD GENERATION BETA BLOCKERS Author keyword 8 100% 1% 5
5 CARDIOL SPORT MED Address 2 28% 2% 7
6 ATLANTA VASC FDN Address 2 67% 0% 2
7 BIOMED SURG SCI MED D Address 2 67% 0% 2
8 DIABET CARDIOVASC EXCELLENCE Address 1 38% 1% 3
9 ALTERED LEFT VENTRICULAR FUNCTION Author keyword 1 100% 0% 2
10 BETA1 ADRENOCEPTOR BLOCKERS Author keyword 1 100% 0% 2

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 NEBIVOLOL 186 59% 46% 210 Search NEBIVOLOL Search NEBIVOLOL
2 VASODILATING BETA BLOCKERS 13 80% 2% 8 Search VASODILATING+BETA+BLOCKERS Search VASODILATING+BETA+BLOCKERS
3 NEBIVOLOL HYDROCHLORIDE 10 73% 2% 8 Search NEBIVOLOL+HYDROCHLORIDE Search NEBIVOLOL+HYDROCHLORIDE
4 THIRD GENERATION BETA BLOCKERS 8 100% 1% 5 Search THIRD+GENERATION+BETA+BLOCKERS Search THIRD+GENERATION+BETA+BLOCKERS
5 ALTERED LEFT VENTRICULAR FUNCTION 1 100% 0% 2 Search ALTERED+LEFT+VENTRICULAR+FUNCTION Search ALTERED+LEFT+VENTRICULAR+FUNCTION
6 BETA1 ADRENOCEPTOR BLOCKERS 1 100% 0% 2 Search BETA1+ADRENOCEPTOR+BLOCKERS Search BETA1+ADRENOCEPTOR+BLOCKERS
7 D L ENANTIOMERS 1 100% 0% 2 Search D+L+ENANTIOMERS Search D+L+ENANTIOMERS
8 DL NEBIVOLOL 1 100% 0% 2 Search DL+NEBIVOLOL Search DL+NEBIVOLOL
9 ERECTILE DYSFUNCTION AND HYPERTENSIVE AGENTS 1 100% 0% 2 Search ERECTILE+DYSFUNCTION+AND+HYPERTENSIVE+AGENTS Search ERECTILE+DYSFUNCTION+AND+HYPERTENSIVE+AGENTS
10 L NEBIVOLOL 1 100% 0% 2 Search L+NEBIVOLOL Search L+NEBIVOLOL

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 FOREARM VASCULATURE 45 66% 9% 42
2 3RD GENERATION BETA BLOCKER 37 75% 6% 27
3 BETA BLOCKER NEBIVOLOL 29 88% 3% 14
4 DL NEBIVOLOL 20 100% 2% 9
5 ANTIHYPERTENSIVE AGENT S R R R NEBIVOLOL 9 83% 1% 5
6 NEBIVOLOL 8 23% 7% 33
7 MEDIATED RELAXATIONS 4 39% 2% 9
8 BLIND RANDOMIZED TRIAL 3 12% 5% 21
9 ESSENTIAL ARTERIAL HYPERTENSION 3 30% 2% 7
10 DISTENSIBILITY IN VIVO 2 44% 1% 4

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol 2008 37 61 87%
Nebivolol Haemodynamic Effects and Clinical Significance of Combined beta-Blockade and Nitric Oxide Release 2010 26 69 57%
Nebivolol: A highly selective beta(1)-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide 2008 33 55 73%
Contemporary Use of beta-Blockers: Clinical Relevance of Subclassification 2014 7 64 28%
Pharmacological mechanisms of clinically favorable properties of a selective beta(1)-adrenoceptor antagonist, nebivolol 2004 35 52 87%
Nebivolol: Vasodilator Properties and Evidence for Relevance in Treatment of Cardiovascular Disease 2014 4 73 38%
Nebivolol: Pharmacologic profile of an ultraselective, vasodilatory beta(1)-blocker 2008 22 98 54%
Nebivolol: third-generation beta-blockade 2007 9 71 85%
Nebivolol: A review of its use in the management of hypertension and chronic heart failure 2006 25 74 64%
Nebivolol: A Third-Generation beta-Blocker for Hypertension 2009 15 47 49%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 CARDIOL SPORT MED 2 28% 1.5% 7
2 ATLANTA VASC FDN 2 67% 0.4% 2
3 BIOMED SURG SCI MED D 2 67% 0.4% 2
4 DIABET CARDIOVASC EXCELLENCE 1 38% 0.7% 3
5 INT CLIN RD 1 100% 0.4% 2
6 SEINSHEIMER CARDIOVASC HLTH PROGRAM 1 29% 0.9% 4
7 CARDIOVASC REGENERAT CARDIOVASC MED 1 50% 0.2% 1
8 CLIN PHARMACOL UNIT CLIN PHARMACOL 1 50% 0.2% 1
9 HYPERTENS RENAL EXCELLENCEMED 1 50% 0.2% 1
10 HYPERTENSSTATE MED GENOM 1 50% 0.2% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000187375 CARVEDILOL//BUCINDOLOL//CARVEDILOL ENANTIOMERS
2 0.0000152679 BISOPROLOL//CARDIOSELECTIVE BETA BLOCKERS//CARDIOSELECTIVE
3 0.0000084731 BETA3 ADRENOCEPTORS//BETA3 ADRENOCEPTOR//ATYPICAL BETA ADRENOCEPTORS
4 0.0000083710 CELIPROLOL//BEVANTOLOL//PERINDOPRIL THERAPEUTIC USE
5 0.0000070592 MINICHAL//ANTIHYPERTENSIVE DRUG CLASSES//ANTIHYPERTENSIVE REGIMENS
6 0.0000057579 HYDROCHLOROTHIAZIDE//AMLODIPINE BESYLATE//LOSARTAN POTASSIUM
7 0.0000057395 AMLODIPINE//BLOOD PRESSURE CONTROL//ANTIHYPERTENSIVE THERAPY
8 0.0000055986 FLOW MEDIATED DILATION//FLOW MEDIATED DILATATION//ENDOTHELIAL FUNCTION
9 0.0000052792 ALPHA BETA ADRENOCEPTOR BLOCKADE//KMUP 1//EUGENOSEDIN A
10 0.0000047215 ANTIHYPERTENSIVE PHARMACOTHERAPY//BETA1 BLOCKADE//CARDIOVASC P REHABIL UNIT